Note: The below is an edited version of an article originally published on BusinessWire. The original article can be read in their entirety here.
The latest data from an ongoing Japanese Phase I/II study of Emicizumab were presented earlier this week at the World Federation of Hemophilia 2016 World Congress. Emicizumab (a product being developed by Chugai Pharmaceutical Co., Roche, and Genentech) is a bispecific antibody for subcutaneous injection under development for hemophilia A. The present study is an extension of a Phase I study investigating safety and exploratory prophylactic efficacy profiles of emicizumab in 18 Japanese hemophilia A patients both with and without FVIII inhibitors. The latest data analysis continued to show a promising profile of once-weekly subcutaneous injection of emicizumab in terms of safety and prophylactic efficacy, regardless of the presence of factor VIII inhibitors.
